Similar articles

• [High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].

  Shirai N, Furuta T. Shirai N, et al. Nihon Rinsho. 2002 Feb;60 Suppl 2:439-44. Nihon Rinsho. 2002. PMID: 11979823 Review. Japanese. No abstract available.
• [Investigation about 3rd line eradication of H. pylori].

  Nakagawa S, Kato M, Shimizu Y, Nakagawa M, Asaka M. Nakagawa S, et al. Nihon Rinsho. 2005 Nov;63 Suppl 11:466-9. Nihon Rinsho. 2005. PMID: 16363580 Review. Japanese. No abstract available.
• [Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].

  Asano M, Taniwaki H, Tsuji D, Sato Y, Shimizu T. Asano M, et al. Nihon Rinsho. 2005 Dec;63 Suppl 12:450-3. Nihon Rinsho. 2005. PMID: 16416832 Review. Japanese. No abstract available.
• Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.

  Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T. Inaba T, et al. J Gastroenterol Hepatol. 2002 Jul;17(7):748-53. doi: 10.1046/j.1440-1746.2002.02790.x. J Gastroenterol Hepatol. 2002. PMID: 12121503 Clinical Trial.
• [Recent topics on important drugs for H. pylori eradication: Rabeprazole].

  Sugimoto M, Furuta T, Nakmura A, Shirai N. Sugimoto M, et al. Nihon Rinsho. 2005 Nov;63 Suppl 11:350-3. Nihon Rinsho. 2005. PMID: 16363558 Review. Japanese. No abstract available.